NCT05836506View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Healthy Volunteer
Interventions
DRUG

ABBV-903 Tablet Form 1

Oral Tablets

DRUG

ABBV-903 Tablet Form 2

Oral Tablets

Trial Locations (1)

60030

Acpru /Id# 254926, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY